APLS Apellis Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: APLS

Price (delayed)

$51.96

Market cap

$6.27B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.45

Enterprise value

$6.02B

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, the company aims ...

Highlights
The gross profit has increased by 46% QoQ
APLS's revenue is up by 45% since the previous quarter
The equity has declined by 16% since the previous quarter but it has increased by 15% year-on-year
The company's quick ratio fell by 33% QoQ and by 33% YoY
The company's gross margin fell by 8% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://apellis.com
Peers: OCX OGEN OLMA OMER

Key stats

What are the main financial stats of APLS
Market
Shares outstanding
120.58M
Market cap
$6.27B
Enterprise value
$6.02B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
31.65
Price to sales (P/S)
15.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.19
Earnings
Revenue
$396.59M
EBIT
-$496.92M
EBITDA
-$495.21M
Free cash flow
-$595.41M
Per share
EPS
-$4.45
Free cash flow per share
-$5.02
Book value per share
$1.64
Revenue per share
$3.34
TBVPS
$6.65
Balance sheet
Total assets
$788.73M
Total liabilities
$594.21M
Debt
$110.93M
Equity
$194.52M
Working capital
$518.74M
Liquidity
Debt to equity
0.57
Current ratio
3.1
Quick ratio
2.26
Net debt/EBITDA
0.49
Margins
EBITDA margin
-124.9%
Gross margin
85.2%
Net margin
-133.3%
Operating margin
-130.4%
Efficiency
Return on assets
-60.4%
Return on equity
-178.5%
Return on invested capital
-197.1%
Return on capital employed
-91.8%
Return on sales
-125.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

APLS stock price

How has the Apellis Pharmaceuticals stock price performed over time
Intraday
0.89%
1 week
-5.73%
1 month
-8.42%
1 year
-35.81%
YTD
-13.2%
QTD
-11.6%

Financial performance

How have Apellis Pharmaceuticals's revenue and profit performed over time
Revenue
$396.59M
Gross profit
$338.08M
Operating income
-$517.12M
Net income
-$528.63M
Gross margin
85.2%
Net margin
-133.3%
The company's net margin has surged by 85% YoY and by 40% QoQ
APLS's operating margin has surged by 83% year-on-year and by 40% since the previous quarter
The gross profit has increased by 46% QoQ
APLS's revenue is up by 45% since the previous quarter

Growth

What is Apellis Pharmaceuticals's growth rate over time

Valuation

What is Apellis Pharmaceuticals stock price valuation
P/E
N/A
P/B
31.65
P/S
15.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.19
The EPS is up by 28% year-on-year and by 15% since the previous quarter
The P/B is 29% more than the 5-year quarterly average of 24.4 and 20% more than the last 4 quarters average of 26.1
The equity has declined by 16% since the previous quarter but it has increased by 15% year-on-year
The stock's price to sales (P/S) is 63% less than its last 4 quarters average of 41.1
APLS's revenue is up by 45% since the previous quarter

Efficiency

How efficient is Apellis Pharmaceuticals business performance
The return on sales has surged by 85% year-on-year and by 41% since the previous quarter
The company's return on invested capital rose by 26% QoQ but it fell by 21% YoY
APLS's ROE is up by 15% QoQ and by 13% YoY
APLS's ROA is up by 13% since the previous quarter and by 12% year-on-year

Dividends

What is APLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for APLS.

Financial health

How did Apellis Pharmaceuticals financials performed over time
Apellis Pharmaceuticals's total assets is 33% more than its total liabilities
The company's quick ratio fell by 33% QoQ and by 33% YoY
The company's current ratio fell by 28% QoQ and by 28% YoY
The company's debt is 43% lower than its equity
The debt to equity has increased by 21% since the previous quarter but it has declined by 14% year-on-year
The equity has declined by 16% since the previous quarter but it has increased by 15% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.